logo-loader
RNS
viewAmryt Pharma PLC

Amryt Pharma PLC - Director/PDMR Shareholding

RNS Number : 0085P
Amryt Pharma PLC
04 June 2020
 

4 June 2020

 

Amryt Pharma plc

("Amryt" or the "Company")

 

Director/PDMR shareholding

This announcement, including the details included in the notification below, is made in accordance with the requirements of the EU Market Abuse Regulation.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1.           

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Ray Stafford

2.

Reason for the notification

a)

Position / status

Non-executive Chairman

b)

Initial notification / amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Amryt Pharma plc

b)

Legal entity identifier

213800YNUJEOJ84L4T95

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Ordinary shares of £0.06 each

 


Identification code

ISIN: GB00BKLTQ412

b)

Nature of the transaction

Purchase of ordinary shares 

d)

Price(s) and volume(s)


Price(s)

Volume(s)



140p

12,500


e)

Aggregated information

-      Aggregated volume

 

-      Aggregated price

 

-      Aggregated total

 

12,500

 

140p

 

£17,500

 

f)

Date of the transaction

3 June 2020

g)

Place of the transaction

London Stock Exchange (AIM)

 

 

Enquiries:                                                                                                                    

Amryt Pharma plc

+353 (1) 518 0200

Joe Wiley, CEO

Rory Nealon, CFO/COO


 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
DSHKKQBDNBKDOAK

Quick facts: Amryt Pharma PLC

Price: 180.99

Market: AIM
Market Cap: £286.87 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Amryt Pharma releases Q-2 financials that show strong revenue growth as...

Amryt Pharma (Nasdaq: AMYT) CEO Dr Joe Wiley joined Steve Darling from Proactive with news the company saw a nice increase in revenue as they released their Q-2 numbers. Dr Wiley talked about some of the numbers and what was driving that revenue. Wiley also told Proactive the company has, for...

1 week ago